Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Weiner LM, Surana R, Wang S.

Nat Rev Immunol. 2010 May;10(5):317-27. doi: 10.1038/nri2744. Review.

2.

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

Alfaro C, Murillo O, Tirapu I, Azpilicueta A, Huarte E, Arina A, Arribillaga L, Pérez-Gracia JL, Bendandi M, Prieto J, Lasarte JJ, Melero I.

An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. Review. Spanish.

3.

Cancer immunotherapy--revisited.

Lesterhuis WJ, Haanen JB, Punt CJ.

Nat Rev Drug Discov. 2011 Aug 1;10(8):591-600. doi: 10.1038/nrd3500. Review.

PMID:
21804596
4.

Monoclonal antibodies for cancer immunotherapy.

Weiner LM, Dhodapkar MV, Ferrone S.

Lancet. 2009 Mar 21;373(9668):1033-40. doi: 10.1016/S0140-6736(09)60251-8. Review.

5.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
6.

The role of membrane complement regulatory proteins in cancer immunotherapy.

Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R.

Adv Exp Med Biol. 2008;632:159-74. Review.

PMID:
19025121
7.

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

Peggs KS, Quezada SA, Allison JP.

Clin Exp Immunol. 2009 Jul;157(1):9-19. doi: 10.1111/j.1365-2249.2009.03912.x. Epub 2009 Feb 18. Review.

8.

Cancer immunotherapy: a treatment for the masses.

Blattman JN, Greenberg PD.

Science. 2004 Jul 9;305(5681):200-5. Review.

PMID:
15247469
9.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
10.

Using antibodies in tumour immunotherapy.

Schultes BC, Nicodemus CF.

Expert Opin Biol Ther. 2004 Aug;4(8):1265-84. Review.

PMID:
15268661
11.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

12.

New approaches for cancer immunotherapy.

Karlitepe A, Ozalp O, Avci CB.

Tumour Biol. 2015 Jun;36(6):4075-8. doi: 10.1007/s13277-015-3491-2. Epub 2015 May 2. Review.

PMID:
25934338
13.

Recent advances using anti-CTLA-4 for the treatment of melanoma.

Sarnaik AA, Weber JS.

Cancer J. 2009 May-Jun;15(3):169-73. doi: 10.1097/PPO.0b013e3181a7450f. Review.

PMID:
19556898
14.

Modulation of CTLA-4 and GITR for cancer immunotherapy.

Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD.

Curr Top Microbiol Immunol. 2011;344:211-44. doi: 10.1007/82_2010_49. Review.

15.

Human Tumor Antigens and Cancer Immunotherapy.

Vigneron N.

Biomed Res Int. 2015;2015:948501. doi: 10.1155/2015/948501. Epub 2015 Jun 16. Review.

16.

Antibody-based immunotherapy of cancer.

Weiner LM, Murray JC, Shuptrine CW.

Cell. 2012 Mar 16;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034. Review.

17.

[Immunotherapy for cancer--modern immunologic strategies in oncology].

Halama N, Zoernig I, Jäger D.

Dtsch Med Wochenschr. 2008 Oct;133(41):2105-8. doi: 10.1055/s-0028-1091251. Epub 2008 Oct 1. Review. German.

PMID:
18985564
18.

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

Chambers CA, Kuhns MS, Egen JG, Allison JP.

Annu Rev Immunol. 2001;19:565-94. Review.

PMID:
11244047
19.

Anti-CD 40 monoclonal antibody.

Geldart T, Illidge T.

Leuk Lymphoma. 2005 Aug;46(8):1105-13. Review.

PMID:
16085550
20.

Next generation of immunotherapy for melanoma.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ.

J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423. Review.

PMID:
18612161
Items per page

Supplemental Content

Write to the Help Desk